Toplantı Özeti
BibTex RIS Kaynak Göster

NOVEL EPIGENETIC BIOMARKER DETERMINATION FOR OSCC BY ARRAY-BASED EPIGENOMIC AND TRANSCRIPTOMIC TECHNIQUES

Yıl 2022, Cilt: 5 Sayı: S-1, 45 - 45, 09.08.2022
https://doi.org/10.26650/JARHS2021-1142702

Öz

Objectives: Oral squamous cell carcinoma (OSCC) has a high morbidity and mortality rates, but there are no reliable biomarkers to define patients in early
phases of disease. In our study (TUBITAK-SBAG-114S497), we aimed to investigate the potential epigenetic biomarker candidate genes observed
methylation-dependent expression loss via methylation and expression array methods in OSCC patients.
Material and Methods: Methylation and expression profiling in tumor and conjugate-normal tissue samples of 6 OSCC patients were analyzed by
“IlluminaHumanMethylation450 chips” and “Illumina iScan”, respectively. Methylation/expression array data were analyzed and interpreted by R(v3.5.1)
environment using ChAMP and limma/lumi packages, and then the significant decreased expression changes due to hypermethylation of the candidate
gene was detected. The selected candidate gene was validated in tumor and matched-normal tissues and body fluids (serum and saliva) of 20 OSCC
patients by QRT-PCR/QMSP methods.
Results: According to the array results, it was determined that the expression levels of the candidate gene were decreased due to methylation
(DiffScore:13.18826; FoldChange:-1.08345). This candidate gene (unpublished data), which plays an important role in ubiquitin-ligase activity, was found
to be methylated in 45% tumor, 40% matched-normal tissue, 10% serum and 30% saliva samples. 50% of the patients observed methylation in the tumor
tissue showed the differentially decreased expression levels.
Conclusion: It is thought that this candidate gene, whose expression level decreased due to methylation, will be a candidate epigenetic biomarker for the
early diagnosis of the subtypes of OSCC. Further validation of this candidate gene will be needed in the larger OSCC cohorts.

Destekleyen Kurum

TUBITAK

Proje Numarası

TUBITAK-SBAG-114S497

Kaynakça

  • Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011;32(4):605-44.

NOVEL EPIGENETIC BIOMARKER DETERMINATION FOR OSCC BY ARRAY-BASED EPIGENOMIC AND TRANSCRIPTOMIC TECHNIQUES

Yıl 2022, Cilt: 5 Sayı: S-1, 45 - 45, 09.08.2022
https://doi.org/10.26650/JARHS2021-1142702

Öz

Objectives: Oral squamous cell carcinoma (OSCC) has a high morbidity and mortality rates, but there are no reliable biomarkers to define patients in early
phases of disease. In our study (TUBITAK-SBAG-114S497), we aimed to investigate the potential epigenetic biomarker candidate genes observed
methylation-dependent expression loss via methylation and expression array methods in OSCC patients.
Material and Methods: Methylation and expression profiling in tumor and conjugate-normal tissue samples of 6 OSCC patients were analyzed by
“IlluminaHumanMethylation450 chips” and “Illumina iScan”, respectively. Methylation/expression array data were analyzed and interpreted by R(v3.5.1)
environment using ChAMP and limma/lumi packages, and then the significant decreased expression changes due to hypermethylation of the candidate
gene was detected. The selected candidate gene was validated in tumor and matched-normal tissues and body fluids (serum and saliva) of 20 OSCC
patients by QRT-PCR/QMSP methods.
Results: According to the array results, it was determined that the expression levels of the candidate gene were decreased due to methylation
(DiffScore:13.18826; FoldChange:-1.08345). This candidate gene (unpublished data), which plays an important role in ubiquitin-ligase activity, was found
to be methylated in 45% tumor, 40% matched-normal tissue, 10% serum and 30% saliva samples. 50% of the patients observed methylation in the tumor
tissue showed the differentially decreased expression levels.
Conclusion: It is thought that this candidate gene, whose expression level decreased due to methylation, will be a candidate epigenetic biomarker for the
early diagnosis of the subtypes of OSCC. Further validation of this candidate gene will be needed in the larger OSCC cohorts.

Proje Numarası

TUBITAK-SBAG-114S497

Kaynakça

  • Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011;32(4):605-44.
Toplam 1 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Klinik Tıp Bilimleri
Bölüm Toplantı Özeti
Yazarlar

Semra Demokan 0000-0002-8066-8419

Sena Sen 0000-0003-3967-8903

Onder Eryılmaz 0000-0001-5717-0244

Sevde Comert 0000-0001-8544-955X

Murat Ulusan 0000-0003-3885-1620

Mehmet Nejat Dalay 0000-0003-1479-3577

Proje Numarası TUBITAK-SBAG-114S497
Yayımlanma Tarihi 9 Ağustos 2022
Gönderilme Tarihi 18 Temmuz 2022
Yayımlandığı Sayı Yıl 2022 Cilt: 5 Sayı: S-1

Kaynak Göster

MLA Demokan, Semra vd. “NOVEL EPIGENETIC BIOMARKER DETERMINATION FOR OSCC BY ARRAY-BASED EPIGENOMIC AND TRANSCRIPTOMIC TECHNIQUES”. Sağlık Bilimlerinde İleri Araştırmalar Dergisi, c. 5, sy. S-1, 2022, ss. 45-45, doi:10.26650/JARHS2021-1142702.